SBFM

Sunshine Biopharma Inc

SBFM, USA

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

https://sunshinebiopharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SBFM
stock
SBFM

Sunshine Biopharma Holds Annual Stockholders Meeting TipRanks

Read more →
SBFM
stock
SBFM

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.25

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-3.65 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-2.81 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-8.09 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 4.08% of the total shares of Sunshine Biopharma Inc

1.

Citadel Advisors Llc

(1.3923%)

since

2025/06/30

2.

Renaissance Technologies Corp

(1.1873%)

since

2025/06/30

3.

Altium Capital Management, LP

(1.1077%)

since

2025/03/31

4.

SBI Securities Co Ltd

(0.1469%)

since

2025/06/30

5.

DFA Emerging Markets I

(0.1136%)

since

2025/07/31

6.

Morgan Stanley - Brokerage Accounts

(0.0842%)

since

2025/06/30

7.

Sabby Management LLC

(0.0342%)

since

2025/06/30

8.

UBS Group AG

(0.0045%)

since

2025/06/30

9.

Advisor Group Holdings, Inc.

(0.0033%)

since

2025/06/30

10.

DFA Emerging Markets II

(0.0013%)

since

2025/07/31

11.

Bank of America Corp

(0.0001%)

since

2025/06/30

12.

TD Waterhouse Canada Inc

(0%)

since

2025/06/30

14.

Connective Capital Management LLC

(0%)

since

2025/03/31

15.

Rise Advisors, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.19

EPS Estimate

-0.09

EPS Difference

-0.1

Surprise Percent

-111.1111%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.